Search Within

Sarat Chandarlapaty

Formats
  1. Meeting Abstract (143)
  2. Journal Article (128)
  3. Review (9)
  4. Editorial (3)
  5. Guidelines (2)
  6. Book Section (1)
  7. Research Letter (1)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (287)
  2. Breast Medicine Service (287)
  3. Department of Medicine (287)
  4. GSK Faculty (287)
  5. Human Oncology and Pathogenesis Program (287)
  6. Solid Tumor Oncology Division (287)

More Groups

People
  1. Pedram Razavi (79)
  2. Jorge Reis-Filho (65)
  3. Neal Rosen (58)
  4. Shanu Modi (51)
  5. Jose Baselga (48)
  6. Britta Weigelt (43)

More People

Years
  1. 2025 (17)
  2. 2024 (30)
  3. 2023 (17)
  4. 2022 (25)
  5. 2021 (23)
  6. 2020 (33)

More Years

Publications
  1. Cancer Research (65)
  2. Journal of Clinical Oncology (53)
  3. Annals of Oncology (21)
  4. Cancer Discovery (11)
  5. Clinical Cancer Research (11)
  6. Laboratory Investigation (11)

More Publications

Publishers
  1. American Association for Cancer Research (90)
  2. American Society of Clinical Oncology (57)
  3. Nature Publishing Group (38)
  4. Oxford University Press (24)
  5. Cell Press (14)
  6. Elsevier Inc. (11)

More Publishers

Results (287)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • mTOR kinase inhibition relieves feedback inhibition of RTK and PI3K signaling in breast cancer cells
    Meeting Abstract

    Rodrik-Outmezguine, V. S.; Chandarlapaty, S.; Cao, N.; Smith, P.; Guichard, S.; Rosen, N.
    Cancer Research (2011)

    Fulltext@MSK | Save
  • Can PI3K/AKT pathway mutations predict for type of recurrence after conservative treatment for DCIS
    Meeting Abstract

    Sakr, R. A.; Andrade, V. P.; Muhsen, S.; Chandarlapaty, S.; Giri, D.; Olvera, N.; Paik, W.; Goldberg, J. I.; Van Zee, K. J.; Rosen, N.; more...
    Cancer Research (2011)

    Fulltext@MSK | Save
  • Inhibition of PI3K-AKT signaling causes a FOXO-dependent induction of receptor tyrosine kinase expression and phosphorylation in cancer
    Meeting Abstract

    Chandarlapaty, S.; Sawai, A.; Rodrik-Outmezguine, V.; Scaltriti, M.; Serra, V.; Baselga, J.; Rosen, N.
    Cancer Research (2011)

    Fulltext@MSK | Save
  • Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I/II study in patients with metastatic HER2-amplified or triple-negative breast cancer
    Meeting Abstract

    Gajria, D.; King, T.; Pannu, H.; Sakr, R.; Seidman, A. D.; Modi, S.; Dickler, M.; Drullinsky, P.; Syldor, A.; Sujata, P.; more...
    Cancer Research (2011)

    Fulltext@MSK | Save
  • A phase II trial of ganetespib: Efficacy and safety in patients (pts) with metastatic breast cancer (MBC)
    Meeting Abstract

    Jhaveri, K.; Chandarlapaty, S.; Lake, D.; Gilewski, T.; Drullinsky, P.; Sugarman, S.; Wasserheit-Leiblich, C.; Moynahan, M. E.; D'Andrea, G.; Haque, S.; more...
    Cancer Research (2011)

    Fulltext@MSK | Save
  • mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling
    Journal Article

    Rodrik-Outmezguine, V. S.; Chandarlapaty, S.; Pagano, N. C.; Poulikakos, P. I.; Scaltriti, M.; Moskatel, E.; Baselga, J.; Guichard, S.; Rosen, N.
    Cancer Discovery (2011)

    Fulltext@MSK | Save
  • HSP90 inhibition is effective in breast cancer: A phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab
    Journal Article

    Modi, S.; Stopeck, A.; Linden, H.; Solit, D.; Chandarlapaty, S.; Rosen, N.; D'Andrea, G.; Dickler, M.; Moynahan, M. E.; Sugarman, S.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Targeted therapy for human epidermal growth factor receptor 2-positive breast Cancer: Can there be too many active drugs?
    Journal Article

    Chandarlapaty, S.; Modi, S.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
    Journal Article

    Serra, V.; Scaltriti, M.; Prudkin, L.; Eichhorn, P. J. A.; Ibrahim, Y. H.; Chandarlapaty, S.; Markman, B.; Rodriguez, O.; Guzman, M.; Rodriguez, S.; more...
    Oncogene (2011)

    Fulltext@MSK | Save
  • Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients
    Journal Article

    Scaltriti, M.; Eichhorn, P. J.; Cortes, J.; Prudkin, L.; Aurac, C.; Jimenez, J.; Chandarlapaty, S.; Serra, V.; Prat, A.; Ibrahim, Y. H.; more...
    Proceedings of the National Academy of Sciences of the United States of America (2011)

    Fulltext@MSK | Save